Forest Expects Lexapro To Gain Market Share Despite Lilly Cymbalta Launch
Executive Summary
Forest is expecting continued market share gains for Lexapro as it prepares for the upcoming launch of Lilly's antidepressant Cymbalta
You may also be interested in...
Forest Expects Multiple Celexa Generics To Enter Market In January
Forest Labs is not putting any "impediments" in the way of generic applications for the antidepressant Celexa (citalopram), President Kenneth Goodman told the Friedman Billings Ramsey growth conference June 2 in New York
Forest Expects Multiple Celexa Generics To Enter Market In January
Forest Labs is not putting any "impediments" in the way of generic applications for the antidepressant Celexa (citalopram), President Kenneth Goodman told the Friedman Billings Ramsey growth conference June 2 in New York
Forest Namenda Has 10% Off-Label Use In Mild-To-Moderate Alzheimer’s
Forest's Alzheimer's disease agent Namenda has 10% off-label use based on early launch data